Therapy for neurodegenerative lysosomal Tay-Sachs (TS) disease requires active Hexosaminidase (Hex) A production in the central nervous system and an efficient therapeutic approach that can act faster than human disease progression. We combined the efficacy of a non-replicating Herpes simplex vector encoding for the Hex A alphasubunit (HSV-T0alphaHex) and the anatomic structure of the brain internal capsule to distribute the missing enzyme optimally. With this gene transfer strategy, for the first time, we re-established the Hex A activity and totally removed the GM2 ganglioside storage in both injected and controlateral hemispheres, in the cerebellum and spinal cord of TS animal model in the span of one month's treatment. In our studies no adverse effects were observed due to the viral vector, injection site or gene expression and, based on these results, we feel confident that the same approach could be applied to similar diseases involving an enzyme defect.
INTRODUCTION
Tay-Sachs disease (TS) is a GM2 gangliosidosis due to the deficiency of the α−subunit of β-hexosaminidase A (1,2) (HEXA gene). In the most severe and typical clinical form, rapid mental and motor deterioration, starting within the first year of life, leads to death within 2-3 years. Pathological features include wide neurodegeneration and neuronal lipid storages. Currently, TS treatment is restricted to supportive care and appropriate management of intervening problems (3).
In mammalian tissues, β-hexosaminidase (Hex, EC 3.2.1.52) exists in two major forms: Hex A (αβ structure) and Hex B (ββ structure) (1, 2) . The homodimer αα, Hex S, represents the residual Hex activity in Sandhoff disease patients, a type 0 GM2 gangliosidosis due to inherited defects in the HEXB gene (4) (5) (6) (7) . Only Hex A, in the presence of the GM2-activator protein, hydrolyses the β-GalNAc-(1-4)-β−Gal glycosidic linkage of the GM2 ganglioside effectively (1, (7) (8) (9) (10) .
Therapy for lysosomal storage disorders with neurological involvement such as TS disease requires production and distribution of the missing enzyme in the Central Nervous System (CNS). Several therapeutic approaches have succeeded in restoring the enzymatic activity to many key tissues (kidney, liver, spleen, etc.) but reduction of GM2 ganglioside deposits in the CNS is difficult to achieve (11) (12) (13) (14) (15) (16) . In fact, the blood-brain barrier, represents a general obstacle to therapy (13, 17, 18) . A further obstacle stems from our observation that the fibroblasts from TS patients are not cross-corrected in vitro by simple administration of the missing enzyme (19) . Moreover, since pre-clinical diagnosis of TS is both a fortunate and sporadic event, a therapeutic approach could be effective if it is able to delay the acute phase of the disease. Therefore restoration of Hex A activity and reduction of GM2 ganglioside storage are primary goals.
Here, we propose an in vivo gene transfer strategy for the production and distribution of the HEXA gene in the CNS of a TS animal model (20) . We used a non-replicating Herpes simplex viral vector since HSV-1 has the ability to infect a wide variety of cell types in the non-replicating phase, e.g. neurons, as well as the intrinsic capacity to be transported in a retrograde manner to motor and/or sensory neuronal cell bodies following peripheral inoculation (21) (22) (23) . We identified the internal capsule as a suitable site of injection. This is a connecting structure mainly involved in motor pathways, which are highly impaired in human TS, that is also affected in Amyotrophic Lateral Sclerosis (24) (25) (26) , and in other genetic neurodegerative diseases (27).
Our data clearly show that the combination of the internal capsule anatomic features, together with the described viral properties, allow a wide distribution of the Hex A activity and the disappearance of the GM2 ganglioside storage in both injected and controlateral brain hemispheres. Interestingly, these results were also obtained for the first time in the cerebellum and in the spinal cord suggesting that this approach is effective in the retardation of the progression of the disease. In our studies we did not observe adverse effects due to the viral vector, injection site or gene expression and based on the results that we have obtained we feel confident that the same approach could be applied to similar diseases involving an enzyme defect. 
RESULTS

Construction
of herpes simplex viral vector encoding for Hex α-subunit cDNA. We produced the non-replicating herpes simplex viral vector containing the human Hex α-subunit cDNA under the control of the ICP0 promoter (28,29) (HSV-T0αHex) (Fig.1a) . ICP0 promoter, which is an immediate early viral promoter, was up-regulated to extremely high levels in a background of a triple mutant replication-deficient vector. The expression cassette, containing the cDNA surrounded by UL41 flanking sequences of HSV, was recombined to UL41 locus of the T0Z viral vector (ICP4 -, 27 -, 22 -, UL41 -/LacZ) (Fig.1a) . We evaluated the insertion of the Hex α-subunit transgene into the viral DNA by southern blot (data not showed).
We used HSV-T0αHex (therapeutic viral vector) and HSV-T0Z (control viral vector) to infect the cells of the CNS of TS mice.
Validation of HSV-T0αHex viral vector by transduction of TS organotypic brain slices To test the efficacy of HSV-
T0αHex viral vector, we transduced organotypic brain slices from TS mice either with the therapeutic or with the control vector, as described in the method section. We evaluated the Hex specific activity in slice extracts using the fluorogenic substrate MUGS, which is only hydrolyzed by Hex isoenzymes containing the α-subunit. Three-day TS organotypic brain slices transduced with the therapeutic viral vector displayed MUGS activity comparable to that found in wild-type slices (Fig.1b) . No MUGS activity was detected either in the untransduced slices or in the slices transduced with control vector from TS mice (Fig.1b) .
In vivo gene transfer strategy for TS disease. We injected the vector into the internal capsule of the left-brain hemisphere (coordinates: -0.34 mm to bregma, 1.4 mm mediolateral, and 3.8 mm depth). We designed an experimental plan composed of five groups of five month-old TS mice. Group 1. TS + HSV-T0αHex, 2.5x10 6 total PFU; group 2.
TS + HSV-T0αHex, 5x10 6 total PFU; group 3. TS + HSV-T0Z, 5x10 6 total PFU; group 4, untreated TS mice; group 5, WT mice.
Therapeutic effect of the HSV-T0αHex viral vector in treated TS mice. Four weeks after injection, we sacrificed the mice, separated the brain hemispheres, the cerebellum and the spinal cord. We dissected each brain hemisphere into 4 rostro-caudal 2.5 mm thick sections and the spinal cord into 3 antero-posterior segments. We analyzed each brain section, as well as the cerebellum and spinal cord, for Hex A activity and for GM2 ganglioside content.
Brain hemisphere analysis. We evaluated the Hex specific activity in the brain section using the fluorogenic substrate MUGS. Fig.2a presents the Hex specific activity toward the MUGS substrate in each brain section of both treated and untreated animals. All TS mice injected with the therapeutic viral vector displayed MUGS activity in the range of normal WT. The injection of TS mice with the highest PFU resulted in the highest increase of the MUGS specific activity. We detected no MUGS activity either in TS mice brain slices infected with the control viral vector or in untreated TS mice. Interestingly, MUGS activity was restored both in the inoculated hemisphere and in the controlateral one.
We verified the correct formation of Hex A isoenzyme in the brain of treated mice by combining the chromatographic analysis on DEAE-cellulose with a specific enzymatic assay employing two different substrates, MUG, hydrolyzed by both α-and β-subunits, and MUGS, hydrolyzed only by α-subunit of hexosaminidases yielding information on the subunit composition of the Hex isoenzymes formed. Under our experimental conditions, Hex B, unretained by the column, was simply eluted with void volume, while Hex A and Hex S were eluted by a linear gradient of NaCl Chromatography also showed the restoration of Hex A isoenzyme in the controlateral TS hemisphere (data not shown).
We analyzed each hemisphere section for the GM2 ganglioside content with Thin Layer Chromatography (TLC). A representative ganglioside chromatographic pattern of treated and untreated brain sections is reported (Fig.3a) .
No variation in the ganglioside pattern was detected in the brain hemispheres of TS mice treated with the higher dose of HSV-T0Z control vector (data not shown). Densitometric analysis of the TLC by 1D Image analysis Software of all the mice investigated demonstrated the disappearance of the accumulated GM2 ganglioside in TS mice treated with the higher dose of HSV-T0αHex viral vector and a decrease of the stored ganglioside in animals treated with the lower dose of the therapeutic viral vector ( Fig.3c and 3d ). These data were observed in all brain sections (both the injected and the controlateral hemispheres) and suggest a dose-dependent gene transfer reversion of the altered phenotype.
Moreover, these data are consistent with the distribution of the Hex A activity.
Cerebellum analysis. We also found the presence of MUGS activity ( Fig.2b) and Hex A isoenzymes (data not shown) in the cerebellum of TS mice treated with the therapeutic viral vector. As for the brain hemispheres, the GM2 ganglioside storage disappeared in the cerebellum of TS mice treated with the higher dose of the HSV-T0αHex viral vector and it was partially removed in TS mice treated with the lower dose of the same vector ( Fig.3b, 3c ).
Spinal cord analysis. No clear restoration of the Hex A activity was detected in the spinal cord probably because the infected cells (Fig.5c ) are distributed along the whole spine and the total number of these cells is rather low.
Distribution of the HSV-T0Z viral vector in treated TS mice.
We analyzed the diffusion of the vector in the brain after treating TS mice with a number of PFU of the HSV-T0Z viral vector corresponding to the higher dose of the therapeutic viral vector used. Animals were sacrificed after 72h and 1 month.
We followed the viral vector distribution by monitoring the X-gal staining in coronal (Fig.4a) , transversal ( trunk which morphologically were undoubtedly of neuronal identity. Positive cells were also located in the cerebellum and controlateral hemisphere ( Fig.4c and Fig.5a ). The presence of X-gal staining in the ependimal layer of Lateral ventricles, third and fourth ventricle, Silvius Aqueductus, indicated that a small part of the vector also spread from the site of injection to other brain areas (Fig. 5b) .We also observed blue cells in the spinal cord. In Fig.5c we report representative X-Gal staining of spinal cord transversal sections of treated TS mice. We observed blue cells in the encephalic trunk; moreover, a few cells (from 12 to 20) were also identified in the distal part of the spinal cord (T8 level the farthest; Fig. 5c ).
DISCUSSION
In this study we delineate a new therapeutic approach for the genetic lysosomal storage disorder Tay-Sachs (TS) disease. Bearing in mind the rapid neurodegeneration and the high lethality of this disease we propose a plan able to delay the acute phase of the disease and to enhance the emergency service gap. We focused our attention on the rapid restoration of Hexosaminidase A activity and the reduction of GM2 ganglioside storage in the CNS since these represent the principle cause of this metabolic alteration. We hypothesize that reduction/prevention of the neural deposits obtained by direct delivery of the missing enzyme into the CNS, could slow down the clinical features of TS.
We designed a strategy which combines the potentiality of HSV-1 non replicating viral vector and the anatomic structure of a chosen injection site to allow wide distribution of Hex A into the CNS.
We delivered a non-replicating herpes-derived viral vector encoding for the Hex A α-subunit cDNA into the brain internal capsule of TS mice to transduce the CNS cells in vivo. This injection site seemed particularly suitable since it contains numerous fiber bundles which make it possible to reach several CNS areas with a single vector administration. Pyramidal tract connects the frontal motor cortex to the midbrain, spinal cord and cerebellum, while the "higher thalamic peduncle" connects the cortex to the thalamus. Other "minor"components connect capsular fibers to the parietal, occipital, and temporal cortex (31). We combined anatomical features of the internal capsule with properties of the herpetic vectors: i) intrinsic capacity to be transported in a retrograde manner to neuronal cell bodies;
ii) ability to infect a wide variety of cell types in the non replicating phase, especially neurons; iii) ability to allow a sustained transgene expression, since the transgene is under the control of ICP0 promoter, (21, 22, (32) (33) (34) which is a target for activation by neuronal transcription factors in neurons that have undergone damage (34) . These features may provide this HSV promoter with the ability to enhance transgene expression under pathological conditions.
All of these HSV features, along with the chosen site of injection, have allowed a long and strong transgene expression and a wide spreading of the missing enzyme into the brain after a single injection (Fig.2-5 ).
We evaluated the efficacy of our strategy by injecting the animal model of TS disease (20) with HSV-T0αHex. We used five month old TS mice because they clearly present GM2 ganglioside storage in the brain. In contrast to human patients, due to the hydrolysis of GM2 ganglioside to GA2 by a murine sialidase, TS mice express a mild form of the disease (35-36). They do not show neurologic symptoms, however they are lacking in Hex A activity (Fig.2) and present a mild storage of GM2 ganglioside in the brain (Fig.3) . Therefore, these mice represent a suitable experimental model for testing the effectiveness of our approach on slowing down the progression of the disease.
We found a decrease in GM2 ganglioside storage in the brains of all TS mice treated with the therapeutic vector which was consistent with the viral vector administration dose. One month after injection, we observed the absence of the GM2 ganglioside storage only in TS mice injected with the higher dose of HSV-T0αHex (Fig.3) . We assume that results obtained with the two different viral doses are due to the different amounts of enzyme production. In fact, TS mice inoculated with the lower dose of HSV-T0αHex only had 40% of MUGS activity levels compared to normal WT mice while the MUGS activity produced in the animals treated with the higher dose of HSV-T0αHex was 60-70% compared to the WT value. The lower level of Hex A activity was insufficient to hydrolyze all the stored GM2 ganglioside. We suspect the lower dose did not transfect enough cells suggesting more time is required to remove the storage material completely.
All treated TS mice showed the depletion of GM2 ganglioside in both injected and non-injected brain hemispheres and in the cerebellum, thus indicating a wide diffusion of the viral construct and/or the therapeutic enzyme. Interestingly, 7 our gene transfer strategy restores the enzymatic activity in TS mice to a range of values comparable to that observed in the WT mice.
We found the presence of the HSV-T0Z control vector in both injected and non-injected hemispheres (Fig.4,5 (Fig.5a ) whereas some are ependymal cells (Fig.5b) .
Interestingly, few X-gal positive cells were present in the cervical and thoracic tract of the spinal cord (Fig. 5c ). This phenomenon strongly reveals the potentiality of this site of injection for the distribution of the transgene throughout the CNS.
According to the vector distribution, Hex A activity was restored in all treated TS mouse brain areas analysed ( Fig. 2 ; Our data are novel since they present the first evidence of the distribution of a therapeutic viral vector throughout the entire CNS and suggest that the anatomic structure of the brain may be a useful tool in therapy for genetic neurodegenerative disorders. In our studies we did not observe adverse effects due to the viral vector, injection site or gene expression and based on the results that we have obtained we feel confident in expressing the opinion that the same approach could be applied to similar diseases involving an enzyme defect.
MATERIALS AND METHODS
Materials. The animal model of TS disease was generated by Yamanaka et al. (20) and bred in our laboratory. C57/bl6 mice were from Charles-River, Italy. The fluorogenic substrates 4-methylumbelliferyl-derivative of β-Nacetylglucosaminide (MUG), of β-N-acetylglucosamine-6-sulphate (MUGS) of 4-methyl-umbelliferone, 5-bromo-4-cloro-2-indlyl-β D-galactopiranoside (X-Gal), Nonidet NP40, agarose gel for electrophoresis, the 2,2,2-tribromoethanol, the 2-methyl-2-butanol, GM2, GM3, and gangliosides mix type III from bovine brain, resorcinol, were from Sigma Chemical Co. Bovine seric albumin and Bio-Rad protein assay reagents were from Bio-Rad Laboratories, DE-52 DEAE-Cellulose was from Whatman Biochemicals. Thin-layer 20x20 CM plates TLC, were form E.Merck A.G.
(Darmstadt, Germany). The medium for tissue culture was from Euro-Clone, Celbio Lab., fetal calf serum was from Mascia Brunelli, penicillin/streptomycin was from Gibco BRL. All other reagents were of analytical grade. The total ganglioside concentration was determined using the resorcinol-HCl method according to Svennerholm with 85:15 butyl-acetate-butyl alcohol as extractant (44) and added to an eppendorf tube containing an equal volume of appropriately diluted upper phase re-suspended in water, mixed well, and heated to 100 °C in a thermo-bloc for 15
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minutes. After addition of 1 ml of extractant and mixing, the samples were cooled on ice water and centrifuged for 3 minutes at 5000 rpm. The solvent layer was recovered and measured at 580 nm wavelengths using a Shimadzu UV- Other analytical methods. Proteins were measured by the method of Bradford (46) using serum bovine albumin as standard. X-Gal staining was carried out according to the method described in the manufacturer's procedure (Boheringer Lab). MUGS, 4-methyumbelliferyl β-N-acetylglucosamine-6-sulfate;
